2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-D0205A
    Carbocisteine 638-23-3 98.0%
    Carbocisteine is an orally active mucolytic agent. Carbocisteine attenuates the phosphorylation of NF-κB p65 and ERK1/2. Carbocisteine modulates Nrf2/HO-1 and NFκB interplay. Carbocisteine inhibits Apoptosis. Carbocisteine is used in chronic obstructive pulmonary disease (COPD) research.
    Carbocisteine
  • HY-P0205B
    Saralasin TFA 2938955-39-4 99.18%
    Saralasin ([Sar1,Ala8] Angiotensin II) TFA is an octapeptide analog of angiotensin II. Saralasin TFA is a competitive angiotensin II receptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension.
    Saralasin TFA
  • HY-P1548A
    β-CGRP, human TFA 99.57%
    β-CGRP, human TFA (Human β-CGRP TFA) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC50s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.
    β-CGRP, human TFA
  • HY-P2818E
    Alkaline Phosphatase, Calf intestinal 9001-78-9
    Alkaline Phosphatase (Apase), Calf intestinal is an alkaline phosphatase from Calf intestinal, and is one of the most active alkaline phosphatases. Alkaline Phosphatase, Calf intestinal is an orally active membrane-bound glycoprotein that catalyzes the hydrolysis of phosphate monoesters at alkaline pH. Alkaline Phosphatase, Calf intestinal reduces myeloperoxidase activity and bacterial translocation. Alkaline Phosphatase, Calf intestinal improves survival rate of mice infected with E. coli. Alkaline Phosphatase, Calf intestinal improves TNBS-induced colon inflammation.
    Alkaline Phosphatase, Calf intestinal
  • HY-P99190
    Eldelumab 946414-98-8 99.50%
    Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease.
    Eldelumab
  • HY-109590R
    Arachidonic acid (Standard) 506-32-1
    Arachidonic acid (Immunocytophyt) (Standard) is the analytical standard of Arachidonic acid (HY-109590). This product is intended for research and analytical applications. Arachidonic acid is an essential fatty acid and a major constituent of biomembranes.
    Arachidonic acid (Standard)
  • HY-111789A
    (S)-Subasumstat 1858282-76-4 98.39%
    (S)-Subasumstat is the isomer of Subasumstat (HY-111789). Subasumstat (TAK-981) is a first in class and selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities.
    (S)-Subasumstat
  • HY-114360A
    Taurohyodeoxycholic acid sodium 38411-85-7 99.99%
    Taurohyodeoxycholic acid (THDCA) sodium is the taurine-conjugated form of the secondary bile acid hyodeoxycholic acid. Taurohyodeoxycholic acid can also reduce the activity and expression of myeloperoxidase TNF-α and IL-6, as well as colonic damage in TNBS-induced ulcerative colitis mouse model.
    Taurohyodeoxycholic acid sodium
  • HY-P990173
    Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) 99.406%
    Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer.
    Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1)
  • HY-P990213
    Anti-Mouse/Human IL-5 Antibody (TRFK5)
    Anti-Mouse/Human IL-5 Antibody (TRFK5) is a rat-derived anti-mouse IL-5 IgG1 κ type antibody inhibitor. Anti-Mouse/Human IL-5 Antibody (TRFK5) can significantly decrease eosinophils. Anti-Mouse/Human IL-5 Antibody (TRFK5) shows potent anti- inflammation effect on pulmonary inflammation and asthma.
    Anti-Mouse/Human IL-5 Antibody (TRFK5)
  • HY-W012184
    CDAP 59016-56-7 99.93%
    CDAP is an organic cyanylating reagent that can be used for preparation of solid phase affinity reagents, modification of protein thiols and nucleotide delivery. CDAP also activates polysaccharides with a variety of chemical properties. CDAP can be used to prepare conjugate vaccines and other immune reagents.
    CDAP
  • HY-W012575
    2,4-Dihydroxybenzoic acid 89-86-1 99.90%
    2,4-Dihydroxybenzoic acid is a degradation product of acid cherry anthocyanins during in vitro cell culture and an analogue of coenzyme Q precursor molecules. 2,4-Dihydroxybenzoic acid can improve the related symptoms of kidney diseases caused by ADCK4/Coq6 deficiency.
    2,4-Dihydroxybenzoic acid
  • HY-W016412
    Coenzyme Q0 605-94-7 ≥99.0%
    Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea. Coenzyme Q0 induces apoptosis and autophagy, suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling.
    Coenzyme Q0
  • HY-W779068
    Chenodeoxycholic acid 3-sulfate disodium 60237-34-5 99.94%
    Chenodeoxycholic acid 3-sulfate disodium is a bile acid. Chenodeoxycholic acid 3-sulfate disodium level corresponds closely with the extent of hepatic dysfunction.
    Chenodeoxycholic acid 3-sulfate disodium
  • HY-113335
    Trihydroxycholestanoic acid 547-98-8 99.48%
    Trihydroxycholestanoic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Refsum Disease, D Bifunctional Protein Deficiency and Infantile Refsum Disease.
    Trihydroxycholestanoic acid
  • HY-161702
    RO6806051 1433901-75-7 99.82%
    RO6806051 is a selectivity FABP4 and FABP5 inhibitor with human FABP4 Ki values of 0.011 μM and 0.23 μM, and human FABP5 Ki values of 0.086 μM and 1.17 μM. RO6806051 can be used for the research of inflammation-related diseases.
    RO6806051
  • HY-30216A
    Leucic acid 498-36-2 ≥98.0%
    Leucic acid (α-Hydroxyisocaproic acid) is an orally active end-product of the microbial metabolism of leucine. Leucic acid can bind to HCAR2, alters AMPK and ERK1/2 phosphorylation status, suppresses lipid synthesis, promotes catabolism, reduces adiposity, enhances lean mass and exercise capacity. Leucic acid suppresses pro-inflammatory cytokine secretion, inflammation-related gene mRNA expression. Leucic acid decreases basal protein synthesis, attenuates myotube atrophy. Leucic acid can be used for the research of obesity.
    Leucic acid
  • HY-D0861A
    EGTA tetrasodium 13368-13-3 99.93%
    EGTA tetrasodium is a cell-impermeant specific calcium ion chelator. EGTA tetrasodium has an apparent calcium dissociation constant (Kd) of 60.5 nM at physiological pH (7.4) and has very high specificity for Ca2+ over Mg2+ (Mg2+ Kd 1-10 mM). EGTA tetrasodium significantly inhibits the substrate adherence capacity of inflammatory macrophages.
    EGTA tetrasodium
  • HY-173154B
    NK7-902 diTFA 99.88%
    NK7-902 diTFA is a selective and orally active CRBN-dependent NEK7 molecular glue degrader with Kd values of 1.5 and 2.6 μM for hNEK7 and mNEK7. NK7-902 diTFA fully degrades NEK7 in human primary monocytes and whole blood but only partially inhibits NLRP3-dependent IL-1β production. NK7-902 diTFA shows activity in murine systems and induces a profound and long-lasting NEK7 degradation but only transiently blocks NLRP3 inflammasome activation. NK7-902 diTFA can be used for the research of inflammation, such as cryopyrin-associated periodic syndromes.
    NK7-902 diTFA
  • HY-12037
    Rigosertib sodium 592542-60-4 99.57%
    Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle. Rigosertib sodium is a selective and non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM.
    Rigosertib sodium
Cat. No. Product Name / Synonyms Application Reactivity